Spain: New Patent Law comes into force

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Spain: New Patent Law comes into force

Law 24/2015 came into force on April 1. It completely modifies the previous Spanish Law 11/1986.

The new Spanish Patent law aims to modernise our legal system and promotes a better fit with European and international patent law. Also, it pursues the eradication of the regulatory dispersion regarding the processing of patents, utility models and supplementary protection certificates (SPCs) and last but not least, reduces and expedites the administrative burden.

Among the most relevant changes that the new law brings along, the implementation of a single patent grant procedure with a substantive examination of patentability is noteworthy. This new procedure will foster the production of stronger patents in Spain. In addition to this important change in the proceeding under new Law, third parties may dispute the validity of a granted patent by filing a post-grant opposition as stated in the European Patent Convention (EPC). Another important novelty is that the search report (IET) on prior art will be issued within the priority year.

Additionally, the scope of utility models is extended to include substances and chemical compositions other than those related to biological materials and pharmaceuticals. Utility models have turned into an attractive alternative for certain inventions not only due to the increase in the scope of protection, but also because of the lack of preliminary examination. For some cases the use of utility models will be more efficient, fast and cost effective than protection through patents.

The present Law introduces the elimination of the exemption of the payment of fees by public universities. From April 1 2017 public universities have a 50% discount on fees which could be even 100% in those cases where inventions have reached the market. Entrepreneurs and SMEs will be paying 50% of fees for filing, preparation of the state of the art reports, conducting substantive examination and the payment of the three first annuities.

Opinions on the new Law are diverse. Private companies will for sure be those that best adapt to the new system. We expect that the new Patent Law will turn into an extraordinary opportunity to promote innovation in our country, besides pushing a major awareness about the capital importance of protecting R&D results through IP instruments.

Patricia Ramos


PONS IPGlorieta Rubén Darío, 428010 – Madrid SpainTel: +34 917007600Fax: +34 913086103clientes@pons.eswww.ponsip.com

more from across site and SHARED ros bottom lb

More from across our site

Niri Shan, the newly appointed head of IP for UK, Ireland and the Middle East, explains why the firm’s international setup has brought UPC success, and addresses German partner departures
Vlad Stanese joins our ‘Five minutes with’ series to discuss potentially precedent-setting trademark and copyright cases and his love for aviation
Heath Hoglund, president of Via LA, discusses how it sets royalty rates and its plans to build on growth in China
Stobbs stands accused of interfering with the administration of justice after Brandsmiths’ client was subjected to an interim injunction for unjustified threats
The firm, known for its prosecution expertise, discusses its plans following the appointment of a UK-based patent litigation head and two new partners
Ed White at Clarivate provides an exclusive insight into the innovation power clusters reshaping Europe and the Middle East’s IP landscape, and why quality is the new currency of invention
In the first in a new podcast series celebrating the tenth anniversary of IP Inclusive, we look back at the network’s origins and discuss its mission
Rebecca Schwarz at Haynes Boone shares how her team secured victory for biopharma client RedHill in a licensing dispute involving a developmental cancer drug
News of a breakaway firm launching in Germany and a spike in vaccine-related patent applications were also among the top talking points
A flurry of hiring activity among UK firms suggests they are confident of mounting a serious challenge at the UPC
Gift this article